Inactive Instrument

Cubist Pharmaceuticals Inc Stock

Stocks

End-of-day quote Nasdaq
- ^USD	-

14-12-09	Cubist Pharmaceuticals : sales force seen as potential boon for Merck intestinal drug	RE
14-12-09	Cubist Pharmaceuticals : Merck says still plans to buy Cubist, despite patent setback	RE

14-12-09	Cubist Pharmaceuticals : sales force seen as potential boon for Merck intestinal drug	RE
14-12-09	Cubist Pharmaceuticals : Merck says still plans to buy Cubist, despite patent setback	RE
14-12-09	Merck : to take on superbugs with Cubist Pharma buy	RE
14-12-08	AstraZeneca : Merck to take on superbugs with Cubist Pharma buy	RE
14-12-08	Apple : S&P 500 posts worst day since Oct; energy shares sink	RE
14-12-08	Cubist Pharmaceuticals : options unusually active before Merck deal	RE
14-12-05	Cubist Pharmaceuticals : Merck in talks to acquire Cubist Pharmaceuticals for more than $7 billion - NYT	RE
13-05-20	Cubist Pharmaceuticals Inc : U.S. court ruling favors Cubist in patent case versus Hospira	RE

15-01-13	Cubist Pharmaceuticals : Announces Withdrawal of Listing of CVRs (CBSTZ) from NASDAQ Global Select Market	BU
14-12-19	Cubist Pharmaceuticals : Announces FDA Approval of New Antibiotic ZERBAXA™ (Ceftolozane/Tazobactam) for Complicated Urinary Tract and Complicated Intra-abdominal Infections	BU
14-12-09	Cubist Pharmaceuticals : Ryan & Maniskas, LLP : Announces Investigation of Cubist Pharmaceuticals Inc.	PR
14-12-08	Cubist Pharmaceuticals : Comments on CUBICIN Patent Litigation	BU
14-12-08	CUBIST PHARMACEUTICALS : ALERT: Johnson & Weaver, LLP Investigates the Fairness of Price and Process in Proposed Sale of Cubist Pharmaceuticals, Inc. to Merck	BU

14-12-21	Cubist Pharmaceuticals : meldet FDA-Zulassung seines neuen Antibiotikums ZERBAXA™ (Ceftolozan/Tazobactam) für komplizierte Harnwegsinfektionen und komplizierte intraabdominelle Infektionen
14-12-20	Cubist Pharmaceuticals : annonce l’approbation par la FDA du nouvel antibiotique ZERBAXA™ (ceftolozane/tazobactam) pour le traitement des infections urinaires compliquées et des infections intra-abdominales compliquées
14-12-09	Merck : compte toujours acheter Cubist malgré un souci sur le Cubicin
14-12-08	Cubist Pharmaceuticals : Merck & Co acquiert Cubist Pharma pour 8,4 milliards de dollars
14-12-08	Cubist Pharmaceuticals : Wall Street ouvre en baisse, l'Asie inquiète

Manager	Title	Age	Since
Karen Rogers PRN	Corporate Officer/Principal	-	-
Phyllis Rae Abbuhl SAM	Sales & Marketing	-	-
Frederick B. Oleson PRN	Corporate Officer/Principal	-	1996-12-31

Director	Title	Age	Since
Martin Hermanus Soeters BRD	Director/Board Member	72	2006-08-31
Kenneth J. Martin BRD	Director/Board Member	72	2013-09-24

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ELI LILLY AND COMPANY	-0.46%	+10.31%	+63.52%	+143.15%	1,257B
JOHNSON & JOHNSON	-0.97%	+1.60%	+43.25%	+80.09%	651B
ABBVIE INC.	-2.05%	+0.73%	+32.47%	+101.62%	510B
ROCHE HOLDING AG	-0.14%	-0.58%	+52.87%	+67.21%	388B
MERCK & CO., INC.	-0.78%	+5.51%	+72.55%	+44.25%	366B
NOVARTIS AG	+0.68%	+2.84%	+33.11%	+58.92%	303B
ASTRAZENECA PLC	+0.09%	+8.13%	+12.13%	+35.00%	288B
AMGEN INC.	-0.12%	+4.68%	+55.97%	+74.59%	252B
GILEAD SCIENCES, INC.	-0.21%	+7.34%	+42.19%	+109.69%	211B
Average	-0.19%	+4.59%	+45.34%	+79.39%	469.63B
Weighted average by Cap.	-0.38%	+5.30%	+49.25%	+93.71%

Employees

Sector